These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9357089

  • 1. Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs.
    Armijo JA, Cuadrado A, Bravo J, Arteaga R.
    Ther Drug Monit; 1997 Oct; 19(5):491-8. PubMed ID: 9357089
    [Abstract] [Full Text] [Related]

  • 2. [In children with refractory epilepsy: vigabatrin or lamotrigine?].
    Caviedes BE, Herranz JL, Arteaga R, Armijo JA.
    Rev Neurol; 1997 Oct; 28(5):444-8. PubMed ID: 10229954
    [Abstract] [Full Text] [Related]

  • 3. Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy.
    Jedrzejczak J, Dławichowska E, Owczarek K, Majkowski J.
    Epilepsy Res; 2000 Apr; 39(2):115-20. PubMed ID: 10759299
    [Abstract] [Full Text] [Related]

  • 4. [Vigabatrin: results with a new antiepileptic agents in 57 patients in a general neurological practice].
    van der Zwan A, van der Zwan A.
    Ned Tijdschr Geneeskd; 1994 Sep 10; 138(37):1859-63. PubMed ID: 7935922
    [Abstract] [Full Text] [Related]

  • 5. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study.
    Feucht M, Brantner-Inthaler S.
    Epilepsia; 1994 Sep 10; 35(5):993-8. PubMed ID: 7925171
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?
    McKee PJ, Blacklaw J, Friel E, Thompson GG, Gillham RA, Brodie MJ.
    Epilepsia; 1993 Sep 10; 34(5):937-43. PubMed ID: 8404750
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Johannessen SI, Tomson T.
    Clin Pharmacokinet; 2006 Sep 10; 45(11):1061-75. PubMed ID: 17048972
    [Abstract] [Full Text] [Related]

  • 8. Vigabatrin withdrawal randomized study in children.
    Chiron C, Dulac O, Gram L.
    Epilepsy Res; 1996 Nov 10; 25(3):209-15. PubMed ID: 8956918
    [Abstract] [Full Text] [Related]

  • 9. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study.
    Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T.
    Ther Drug Monit; 2003 Aug 10; 25(4):457-62. PubMed ID: 12883229
    [Abstract] [Full Text] [Related]

  • 10. Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.
    Bélanger S, Coulombe G, Carmant L.
    Epilepsia; 1998 Aug 10; 39(8):878-83. PubMed ID: 9701380
    [Abstract] [Full Text] [Related]

  • 11. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications.
    Armijo JA, Bravo J, Cuadrado A, Herranz JL.
    Ther Drug Monit; 1999 Apr 10; 21(2):182-90. PubMed ID: 10217338
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study.
    Dalla Bernardina B, Fontana E, Vigevano F, Fusco L, Torelli D, Galeone D, Buti D, Cianchetti C, Gnanasakthy A, Iudice A.
    Epilepsia; 1995 Jul 10; 36(7):687-91. PubMed ID: 7555986
    [Abstract] [Full Text] [Related]

  • 13. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.
    Dodrill CB, Arnett JL, Sommerville KW, Sussman NM.
    Epilepsia; 1995 Feb 10; 36(2):164-73. PubMed ID: 7821274
    [Abstract] [Full Text] [Related]

  • 14. The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism.
    Spanaki MV, Siegel H, Kopylev L, Fazilat S, Dean A, Liow K, Ben-Menachem E, Gaillard WD, Theodore WH.
    Neurology; 1999 Oct 22; 53(7):1518-22. PubMed ID: 10534261
    [Abstract] [Full Text] [Related]

  • 15. Gamma-vinyl GABA (vigabatrin) and mood disturbances.
    Aldenkamp AP, Vermeulen J, Mulder OG, Overweg J, Van Parys JA, Beun AM, Van 't Slot B.
    Epilepsia; 1994 Oct 22; 35(5):999-1004. PubMed ID: 7925172
    [Abstract] [Full Text] [Related]

  • 16. Visual field loss associated with vigabatrin: quantification and relation to dosage.
    Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TT, Stilma JS.
    Epilepsia; 2001 Feb 22; 42(2):262-7. PubMed ID: 11240600
    [Abstract] [Full Text] [Related]

  • 17. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial.
    Cramer J, Vachon L, Desforges C, Sussman NM.
    Epilepsia; 1995 Nov 22; 36(11):1111-7. PubMed ID: 7588455
    [Abstract] [Full Text] [Related]

  • 18. Visual fields at school-age in children treated with vigabatrin in infancy.
    Gaily E, Jonsson H, Lappi M.
    Epilepsia; 2009 Feb 22; 50(2):206-16. PubMed ID: 19215279
    [Abstract] [Full Text] [Related]

  • 19. A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data.
    Yu DK, Hutcheson SJ, Wei G, Bhargava VO, Weir SJ.
    Biopharm Drug Dispos; 1994 Aug 22; 15(6):473-84. PubMed ID: 7993985
    [Abstract] [Full Text] [Related]

  • 20. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group.
    Arzimanoglou AA, Dumas C, Ghirardi L.
    Seizure; 1997 Jun 22; 6(3):225-31. PubMed ID: 9203252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.